Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + remifentanil + sufentanil
- Development stage
- Phase 4
- Lead developer
- AkzoNobel
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of three anesthetic agents used for total intravenous anesthesia (TIVA). Propofol is a short-acting intravenous anesthetic agent, remifentanil is a potent short-acting synthetic opioid with rapid onset and recovery, and sufentanil is a powerful synthetic opioid approximately 5-10 times more potent than fentanyl. This combination provides effective sedation, analgesia, and anesthesia while potentially reducing the individual doses needed of each component, resulting in improved hemodynamic stability and reduced stress responses during surgical procedures.
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on propofol + remifentanil + sufentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + remifentanil + sufentanil.